Hanmi Pharmaceutical Co. Ltd., of Seoul, Korea, presented interim results of the phase I/II domestic trial of HM61713, an orally active epidermal growth factor receptor (EGFR) mutant selective inhibitor, in T790M mutation-positive non-small-cell lung cancer patients. Daily single administration of HM61713 800 mg showed 95.2 percent disease control rate (DCR) in 59 of 62 patients with T790M-positive mutation who developed resistance to previous EGFR tyrosine kinase inhibition.